Printer Friendly

DURAMED ANSWERS NATIONAL CALL FOR TUBERCULOSIS DRUG

 DURAMED ANSWERS NATIONAL CALL FOR TUBERCULOSIS DRUG
 CINCINNATI, March 30 /PRNewswire/ -- Duramed Pharmaceuticals, Inc.


will re-enter the tuberculosis medication market with Isoniazid, the generic equivalent of the brand drug INH, Duramed chairman and president E. Thomas Arington announced today.
 Arington also announced that the company had received U.S. Food and Drug Administration (FDA) approval of its manufacturing process validation on March 26, 1992. In response to the urgent need for this critical medication, Duramed will begin shipping immediately.
 Recently, the number of tuberculosis cases in the United States has risen steadily, and worldwide it causes more deaths than any other infectious disease. Current estimates are that eight million people will develop active tuberculosis each year, and three million will die as a result.
 "The recent resurgence of tuberculosis has created an increased demand for affordable medication to treat the disease," Arington stated. "Our decision to resume manufacturing and marketing Isoniazid is in direct response to that need."
 Duramed Pharmaceuticals, Inc. manufactures and sells generic drug products composed of various dosages of prescription and over-the-counter drugs.
 -0- 3/30/92
 /CONTACT: Bill Roberts or John Maginnis, public relations consultants, Cameron Towey Central, 513-891-1818, for Duramed Pharmaceuticals, Inc./ CO: Duramed Pharmaceuticals, Inc. ST: Ohio IN: MTC SU:


KK -- CL015 -- 2882 03/30/92 12:10 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 30, 1992
Words:215
Previous Article:GREAT LAKES BANCORP SHAREHOLDER REQUESTS SPECIAL MEETING
Next Article:NATION'S TOP LAW FIRMS JOIN NATIONAL UNION PANEL COUNSEL TO REPRESENT D&O INSUREDS
Topics:


Related Articles
DURAMED FILES CONJUGATED ESTROGENS PRODUCT APPLICATION
DURAMED ENTERS INTO DEFINITIVE AGREEMENT FOR ACQUISITION OF HALLMARK PHARMACEUTICALS, INC.
Duramed Confident After FDA Releases Conjugated Estrogens Analysis
Duramed's Conjugated Estrogens Remains Under Active Review
FDA Authorizes Duramed Pharmaceuticals, Inc. to Market Prochlorperazine Tablets
Duramed Pharmaceuticals Inc. Comments on Newsday Article
Duramed Petitions Food & Drug Administration to Declare that Premarin Be Required to Include Each Active Ingredient on its Label
Cenestin Offers Baby Boomer Women a New Plant-Derived Alternative to Horse Urine-Derived Premarin.
/FROM PR NEWSWIRE CLEVELAND 216-566-7777/ TO BUSINESS EDITOR:.
Duramed Pharmaceuticals, Inc. Files Antitrust Lawsuit Against Wyeth-Ayerst Laboratories, Inc.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters